JDS Pharma
ActiveSummary
JDS Pharma has been active since 2024 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €43,542 and a net result of €30,345. Its solvency ranks better than 79% of 22,260 sector peers (NACE 47, financial year 2025). The computed 12-month bankruptcy probability is 0.4% (very low).
History
Acts, filings and financial milestones
Next filing, financial year 2026, expected by
2026
31-08
NBB filing
Annual accounts filed
financial year 2025 · micro format · 31 days late
2025
23-06
NBB filing
Annual accounts filed
financial year 2024 · micro format
2024
02-09
Gazette deed
IncorporationAppointment: DI SCIACCA Julie (director) · Founder · Founding capital12 facts ▸
Gazette deed
Incorporation
Appointment: DI SCIACCA Julie (director) · Founder · Founding capital12 facts ▸
- Incorporation, 29-08-2024
- Founder, DI SCIACCA Julie
- Founding capital, €3,000
- Other provision, “plan financier, fondateur” (deed in French)
- Other provision, “capitaux propres suffisants à la constitution, capitaux propres qui, compte tenu des autres sources de financement, soient suffisants à la lumière de l’activité…” (deed in French)
- Bank account, “banque à choisir par la comparante, compte bancaire à ouvrir au nom de la société” (deed in French)
- Declaration, “absence d’avantages particuliers, pas d’avantages particuliers attribués au fondateur ou à une personne ayant participé directement ou indirectement à la consti…” (deed in French)
- Other provision, “TVAC, frais de constitution” (deed in French)
- Capital
- Declaration, “autorisations préalables, société pourrait devoir obtenir attestations, autorisations ou licences préalables en raison des règles administratives en vigueur” (deed in French)
- Director appointment, DI SCIACCA Julie (director (not named in the articles))
- Other provision, “pas pour l’instant, coordonnées électroniques” (deed in French)
Gazette deedNBB filing
1 of 1 deed read